MAIN


©1994-2018 All Rights Reserved. Online Journal of Veterinary Research. You may not store these pages in any form except for your own personal use. All other usage or distribution is illegal under international copyright treaties. Permission to use any of these pages in any other way besides the before mentioned must be gained in writing from the publisher. This article is exclusively copyrighted in its entirety to OJVR publications. This article may be copied once but may not be, reproduced or re-transmitted without the express permission of the editors


OJVRTM

 

Online Journal of Veterinary Research©

Volume 12 (1) :15-26, 2008. Redacted 2018.


Veterinary Clinical Drug Development and Registration: dynamics of healthcare transaction

to achieve successful economic outcomes.

 

Lloyd Reeve-Johnson,  BVM&S, DVMS, PhD, DipECVPT, PGCert, FIBiol, FRCVS.

 

 

Goyd Project Solutions, Goyd Park, 79 Layfield Road, Anstead Q4070 , Australia Contact: projectmanagement@goydpark.com web address: www.goydpark.com§

 

ABSTRACT

 

Reeve-Johnson L, Veterinary Clinical Drug Development and Registration – dynamics of the ‘healthcare transaction’ to achieve successful economic outcomes. Onl J Vet Res., 12 (1) :15-26, 2008. Success or failure of an investment to develop a new veterinary product is ultimately dependent upon the perception of the safety and efficacy by the regulator, veterinary clinician and animal owner.  The most costly and time-expensive phase of product development is the pre-registration clinical efficacy testing.  Disease modeling techniques have been used to attempt to save both development time and cost.  While they are valuable predictive indicators, there are limitations to the transferability of this data to effectiveness in the clinic.  This paper examines the decision sequence of the veterinary healthcare system using modeling approaches to better understand the interplay between the patient/client/clinician team making the decision whether or not to choose a product, and the  pharmaceutical company and government regulator who determine which products are made available to the market.  All participants influence the adoption / use of products, but differ in the relative level of influence.  It is useful to understand how the adoption of therapeutic products can be influenced both for development and product registration purposes as well as to assure ultimate financial return in the marketplace.

 

Key words: “veterinary product registration, regulatory affairs, consultancy”


BACK TO MAIN PAGE

 

FULL-TEXT (SUBSCRIPTION OR PURCHASE TITLE $25USD)